USPH (US Physical Therapy) Research & Development: $0.0 Mil (TTM As of Mar. 2026)


USPH US Physical Therapy Inc USPH
77 GF Score
Price $66.21
GF Value $107.60
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is US Physical Therapy Research & Development?

US Physical Therapy USPH +4.27% 77 Research & Development is $0.0 Mil as of Mar. 2026. GuruFocus rates USPH with a GF Score™ of 77/100 and a GF Value™ of $107.60 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. US Physical Therapy's Research & Development for the three months ended in Mar. 2026 was $0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0.0 Mil.

US Physical Therapy  (NYSE:USPH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

US Physical Therapy Research & Development Related Terms

US Physical Therapy Research & Development Historical Data

* Premium members only.

The historical data trend for US Physical Therapy's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

US Physical Therapy Research & Development Chart

US Physical Therapy Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

US Physical Therapy Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
USPH
77GF Score
US Physical Therapy Inc USPH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

US Physical Therapy Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.0 Mil mean?
US Physical Therapy (USPH) has a Research & Development of $0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on US Physical Therapy and its competitors.
Is US Physical Therapy's Research & Development too high?
US Physical Therapy's current Research & Development is $0.0 Mil. Overall, US Physical Therapy has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does US Physical Therapy's Research & Development compare to INNV and NUTX?
US Physical Therapy's Research & Development of $0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on US Physical Therapy and its competitors. US Physical Therapy's current Research & Development is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is US Physical Therapy stock overvalued right now?
Based on GuruFocus' analysis, US Physical Therapy (USPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $107.60, compared to a current price of $66.21 — trading 38.5% below its estimated fair value. The current Research & Development is $0.0 Mil. US Physical Therapy's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For US Physical Therapy (USPH), the current Research & Development is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is US Physical Therapy (USPH) Overvalued in 2026?

Based on GuruFocus' analysis, US Physical Therapy stock appears to be undervalued. The current stock price of $66.21 is trading 38.5% below its estimated GF Value™ of $107.60. GuruFocus considers US Physical Therapy to be Significantly Undervalued.

Key valuation signals for USPH:

  • Research & Development: $0.0 Mil
  • GF Value™: $107.60 vs. price of $66.21 (38.5% below fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the USPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

US Physical Therapy Business Description

Address 1300 West Sam Houston Parkway South, Suite 300, Houston, TX, USA, 77042
US Physical Therapy Inc through its subsidiaries operate outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
77GF Score

Get the complete analysis for USPH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$66.21
Price
$107.60
GF Value